Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.
The deal is Salk's second broad-based research pact with a drug maker in as many years: In early 2008 the non-profit biological research institute signed a similar deal in the area of inflammation with French specialty pharma Ipsen.
The company also noted in a filing with the US Securities and Exchange Commission that it continues to seek out industry partnerships after having failed to forge a deal in 2008 as previously anticipated.
Cenix BioScience, AstraZeneca, RXi Pharmaceuticals, Dicerna Pharmaceuticals, Intradigm, US Patent and Trademark Office, Integrated DNA Technologies, VH Bio, Asuragen, Agilent Technologies, Proceedings of the National Academy of Sciences
If the drug reaches the market, likely through a partnership with a pharma, UC Davis stands to receive a "modest" royalty based on sales of the drug as part of an exclusive licensing agreement it signed with Arete.
A European research team has developed an approach that uses information about positional weight matrices, comparative genomics, and gene expression profiling to find Stat3 transcription factor binding sites in the mouse genome.